ART Advanced Research Technologies Inc.
TSX : ARA

ART Advanced Research Technologies Inc.

September 07, 2007 07:05 ET

ART Advanced Research Technologies Inc. Presents Research Utilizing Optix and Fenestra Products at Joint Molecular Imaging Conference in Rhode Island

MONTREAL, QUEBEC--(Marketwire - Sept. 7, 2007) - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced today that it will participate in a number of presentations relating to its Optix® and Fenestra® products at the Joint Molecular Imaging Conference of the Academy of Molecular Imaging (AMI) and the Society for Molecular Imaging (SMI), being held at the Rhode Island Convention Center in Providence, Rhode Island, from September 7 to 11, 2007.

Scientific presentations featuring research based on the Optix in vivo fluorescence optical imaging system include:

Presentation Number: 0150. Utilizing Fluorescence Lifetime Imaging to Noninvasively Track Near-Infrared-Emissive-Dendritic Cells In Vivo. Natalie A. Christian, Fabian Benencia, Guizhi Li, Paul Frail, Michael J. Therien, George Coukos, Daniel A. Hammer, University of Pennsylvania, USA. Tuesday, September 11, 2007, 1:30 pm - 3:15 pm, Session 27, Exhibit Hall A.

Presentation Number: 0378. Development of a near infrared reporter system for in vivo imaging. Elisabeth Silden(1), Emmet McCormack(1), David Micklem(2), Bjorn Tore Gjertsen1, James Lorens(2), (1)Institute of Medicine, Haukeland University Hospital, University of Bergen, Norway; 2Institute for Biomedicine, University of Bergen, Norway. Sunday, September 9, 2007, 4:00 pm - 5:00 pm, Session P03, Exhibit Hall A.

Presentation Number: 0642. Development and evaluation of labeled antibodies as optical contrast reagents in acute myeloid leukemia (AML). Maja Mujic(1), Emmet McCormack(1), Anita Ryningen(1), Alexandre Belenkov(2), Oystein Bruserud(1), Bjorn Tore Gjertsen(1), 1Haukelad University Hospital, Norway; (2)ART Advanced Research Technologies Inc., Canada. Monday, September 10, 2007, 3:30 pm - 4:30 pm, Session P10, Exhibit Hall A.

Presentation Number: 0778. Diffuse optical fluorescence imaging: sensitivity to heterogeneities and autofluorescence. Frederic Leblond, Nicolas Robitaille, Simon Fortier, Niculae Mincu, Jean Brunette, Mario Khayat, ART Advanced Research Technologies Inc., Canada. Monday, September 10, 2007, 3:30 pm - 4:30 pm, Session P14, Exhibit Hall A.

Presentation Number: 0827. In vivo optical imaging of p53 specific targeted therapy in Acute Myeloid leukaemia. Gurid Venaas, Emmet Mc Cormack, Ingvild Haaland, Nina Anesen, Oystein Bruserud, Bjorn Tore Gjertsen, Institute for Internal Medicine, Haukeland University Hospital, University of Bergen, Norway. Tuesday, September 11, 2007, 4:00 pm - 5:00 pm, Session P15, Exhibit Hall A.

Presentation Number: 0864. Design and Performance Analysis of a Small-animal Fluorescence Tomography System Coupled to MicroCT. Dax Kepshire(1), Michael Hutchins(2), Annie Provencher(2), Niculae Mincu(2), Frederic Leblond(2), Josiah Gruber(1), Brian Pogue(1), Mario Khayat(2), (1)Dartmouth College, USA; (2)ART Advanced Research Technologies Inc., Canada. Tuesday, September 11, 2007, 4:00 pm - 5:00 pm, Session P16, Exhibit Hall A.

Presentation Number: 0871. Molecular Imaging of Brain Tumors Targeted Using Single Domain Antibodies. Umar Iqbal(1), Abulrob Abedelnasser(1), Ulrike Trojahn(2), Andrea Bell(1), Jianbing Zhang(1), Maureen O'Connor-McCourt(2), Roger MacKenzie(1), Danica Stanimirovic(1), 1Institute of Biological Sciences, National Research Council, Canada; (2)Biotechnology Research Institute, National Research Council, Canada. Tuesday, September 11, 2007, 4:00 pm - 5:00 pm, Session P16, Exhibit Hall A.

Presentation Number: 0958. Single-Domain Antibody (FC5)-Mediated Brain Delivery of Doxorubicin-Loaded Immunoliposomes. Abedelnasser Abulrob, Umar Iqbal, Eric Brunette, Danica Stanimirovic, Institute for Biological Sciences, National Research Council of Canada, Canada. Tuesday, September 11, 2007, 4:00 pm - 5:00 pm, Session P18, Exhibit Hall A.

Separately, scientific research highlighting work done using ART's Fenestra contrast agents for microCT imaging is featured in several scientific presentations:

Presentation Number: 0725. Longitudinal Assessment of Murine Cardiac Function Using In Vivo Contrast-Enhanced Gated MicroCT. Timothy C. Doyle, Ahmad Y. Sheikh, Maryam K. Sheikh, Feng Cao, Phillip C. Yang, Robert C. Robbins, Joseph C. Wu, Stanford University, USA. Sunday, September 9, 2007, 3:30 pm - 4:30 pm, Session P13, Exhibit Hall A.

Presentation Number: 0947. Fenestra LDHD, a Higher Concentration Formula for MicroCT Liver Contrast Enhancement, Evaluated in SCID Mice Over Time and Dose. Chris E. Suckow, David B. Stout, UCLA School of Medicine Department of Molecular and Medical Pharmacology, USA. Monday, September 10, 2007, 4:00 pm - 5:00 pm, Session P17, Exhibit Hall A.

Full texts of the abstracts can be obtained through the meeting program page (http://www.molecularimaging.org/2007jointconf/program07.php) and following the link labelled "Joint Conference Program Planner".

ART is also presenting the Optix and Fenestra product offering as an exhibitor at the event (booth #411), in the Exhibit Hall of the Rhode Island Convention Center.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2006, available on SEDAR (www.sedar.com).

Contact Information

  • ART Advanced Research Technologies Inc.
    Jacques Bedard
    Chief Financial Officer
    jbedard@art.ca
    or
    ART Advanced Research Technologies Inc.
    Mario Khayat
    Vice President, Optical Products
    514-832-0777
    mkhayat@art.ca
    www.art.ca